Opt-out from biobanks better respects patients'autonomy

摘要

We found that dissent to storage and use of samples by Swedish healthcare biobanks is rare and does not pose a threat to research, concluding that the results give prima facie reason to consider a move to an opt-out system.Laurie presented two controversies as evidence that opt-out systems are inappropriate. However, despite the controversy surrounding the Icelandic health sector database, public support continues. Furthermore, negative attitudes may in part arise from commercial interests, which are largely absent in the Swedish context. The second example was organ donation in England, which should not be confused with biobank research.